Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Gut microbiomes can predict non-alcoholic fatty liver disease

May 19, 2017 By Danielle Kirsh

bacteria non-alcoholic fatty liver disease

[Image from Peter Handke on Flickr]

There is a microbe in stool samples that can predict non-alcoholic fatty liver disease (NAFLD), according to researchers at the University of California San Diego School of Medicine.

NAFLD occurs when there is a build up extra fat in liver cells that isn’t caused by alcohol, according to the American Liver Foundation. The liver has some natural fats on it, but if more than 5–10% of the liver’s weight is fat, then it is considered a fatty liver. NAFLD usually affects people who are overweight and obese or have diabetes, high cholesterol or high triglycerides. It affects up to a quarter of people in the U.S.

“We estimate that as many as 100 million adults and children in the U.S. may have NAFLD. Determining exactly who has or is at risk for the disease is a critical unmet medical need,” said Rohit Loomba, professor of medicine in the division of gastroenterology and first author on the study, in a press release. “There are about 50 new NAFLD drugs in the pipeline, including about 5 that will likely be approved for use in the next 2 years. If we are better able to diagnose this condition, we will be better at enrolling the right types of patients in these trials, and ultimately will be better equipped to prevent and treat it.”

The researchers studied 135 participants in this study and found that the gut microbiome could predict advanced NAFLD with 88–94% accuracy.

The first group of participants included 86 patients who were diagnosed with NAFLD through a biopsy. 72 of them had mild to moderate NAFLD and 14 had advanced disease. The researchers had the microbial genes that were extracted from stool samples sequenced by collaborators at Human Longevity Inc. to figure out which species were living where and how many there was. The researchers saw 37 bacterial species that could differentiate between mild/moderate NAFLD and advanced disease. They could predict the patients who had the advanced disease with 93.6% accuracy.

A second study group evaluated 16 patients with advanced NAFLD and 33 healthy people. There were 9 bacterial species that were found that allowed the researchers to distinguish between the NAFLD patients and healthy participants with 88% accuracy.

The research team also found that patients who had advanced NAFLD were more likely to have the bacteria Proteobacteria in their stool and fewer Firmicutes bacteria in their stool than people with early-stage NAFLD. They also found that the E. coli bacteria was 3 times more common in advanced NAFLD patients than patients in the early stages.

“We believe our study sets the stage for a potential stool-based test to detect advanced liver fibrosis based simply on microbial patterns or at least help us minimize the number of patients who have to undergo liver biopsies,” said senior author and president of the J. Craig Venter Institute Karen E. Nelson.

So far, the method has only been tested on a small number of patients, but the researchers are hopeful in getting to test it in a larger setting. Upon success, the researchers say the test wouldn’t even be available for patients within the next 5 years.

The study also doesn’t suggest that the presence or absence of certain microbial species causes NAFLD, according to Loomba.

“Understanding the microbiome, just as sequencing the human genome, is one part of the puzzle on human health and disease,” said the study’s co-author J. Craig Venter, who is also the co-founder and executive chairman of Human Longevity, Inc. “New technologies, such as machine learning, are allowing for tremendous advances to interpret these data.”

The research was funded by the National Institutes of Health, American Gastroenterological Association Foundation, T. Franklin Williams Scholarship Award, Atlantic Philanthropies, Inc., John A. Hartford Foundation, OM and Association of Specialty Professors. It was published online in the Cell Metabolism journal.

[Want to stay more on top of MDO content? Subscribe to our weekly e-newsletter.]

You may also like:

  • bandaged arm
    10 innovative diagnostic tests to combat diseases

  • New possibilities in diagnostics thanks to miniature flow sensor
  • Arterys
    How deep learning could change diagnostic imaging forever

Related Articles Read More >

A portrait of AcuityMD co-founder and CEO Michael Monovoukas
Device commercialization platform AcuityMD raises $31M Series A to fund R&D engineer hiring
Harvard Science and Engineering Complex SEC SEAS Harvard John A. Paulson School of Engineering and Applied Sciences
Here’s where Harvard’s engineering dean sees medtech research going
An illustration of a cloud-shaped room filled with medical devices
The cloud is transforming medtech: Amazon, Microsoft, Google, J&J, Philips and GE Healthcare leaders explain
MIT GI pressure detection device
MIT researchers think their tube-based device could improve gastrointestinal disorder diagnosis

DeviceTalks Weekly.

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech